Put companies on watchlist
RHÖN-KLINIKUM Aktiengesellschaft
ISIN: DE0007042301
WKN: 704230
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

RHÖN-KLINIKUM Aktiengesellschaft · ISIN: DE0007042301 · EQS - Company News (35 News)
Country: Germany · Primary market: Germany · EQS NID: 2024407
07 November 2024 08:59AM

RHÖN-KLINIKUM AG continues solid performance in the first nine months – outlook confirmed  


EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Quarter Results/9 Month figures
RHÖN-KLINIKUM AG continues solid performance in the first nine months – outlook confirmed  

07.11.2024 / 08:59 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

Corporate News

Bad Neustadt a. d. Saale | 7 November 2024

 

RHÖN-KLINIKUM AG continues solid performance in the first nine months –
outlook confirmed  


RHÖN-KLINIKUM AG continues to report an increase in consolidated revenues and profit. In the first
nine months of financial year 2024, revenues were up by EUR 82.1 million to reach EUR 1,171.1 million
(9M 2023: EUR 1,089.0 million). Consolidated profit improved by 27.7% to EUR 30.4 million (9M 2023: EUR 23.8 million). At EUR 75.1 million, EBITDA was 2.3% above the level in prior year (9M 2023: EUR 73.4 million). From January to September 2023 a total of 688,787 patients were treated on an inpatient and outpatient basis in the hospitals and medical care centres, 3.6% more compared with the same period of the previous year (9M 2023: 664,594).

“We are taking various strategic measures enabling us to achieve a stable performance in this challenging market environment and are prepared for the hospital reform. In this regard, we are focusing on our strengths such as the specialisation of our facilities, the high level of treatment quality as well as the close collaboration within the Group’s network. Moreover, we are reinvesting our earnings in new staff and the infrastructure of our facilities to ensure our processes are effective and efficient”, said Prof. Dr. Tobias Kaltenbach, chairman of the Board of Management of RHÖN-KLINIKUM AG.

Outlook for 2024 confirmed

For the current financial year, RHÖN-KLINIKUM AG continues to expect revenues of EUR 1.6 billion within a range of plus or minus 5%. For earnings before interest, tax and depreciation/amortisation (EBITDA), a level of between EUR 110 million and EUR 120 million is expected.

The outlook is subject to considerable uncertainties in connection with the numerous global crises in the form of inflation and price increases and any regulatory measures impacting our remuneration structure in 2024.

The Quarterly Statement for Q3 2024 is published on the Internet.

 

RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 882,000 patients are treated at our five sites – RHÖN-KLINIKUM Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,200 persons. The innovative RHÖN Campus approach committed to cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are key elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA.   www.rhoen-klinikum-ag.com


Contact:

RHÖN-KLINIKUM AG | Head of Corporate Finance, Treasury, Investor Relations and Sustainability
Julian Schmitt | T. +49 9771 65-12250 | julian.schmitt@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale



07.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a. d. Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 2024407

 
End of News EQS News Service

2024407  07.11.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2024407&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - RHÖN-KLINIKUM Aktiengesellschaft
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.